In BRAF-mutant melanoma, BRAF inhibitors (PLX4032) remarkably can remodel surrounding ECM by activating melanoma-associated fibroblasts (MAFs) through phosphorylation of MLC2/MYL9, which is the key regulator of actomyosin contractility. The gene discussed is MYL9; the disease is melanoma.